...
首页> 外文期刊>Acta bio-medica: Atenei Parmensis >Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
【24h】

Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study

机译:2型糖尿病患者的患病率,临床表现和生物化学数据与Covid-19的非糖尿病症状患者 - 19:比较研究

获取原文
           

摘要

Background: There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with -COVID-19 infection in comparison with non-diabetic patients. Aim of the study: We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were -assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 -supplementation were assessed. Results: Prevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%). Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic -patients (0.28 ± 0.8; p: 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: 0.01). Conclusions: T2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use.
机译:背景:与非糖尿病患者相比,有关2型糖尿病患者(T2DM)(T2DM)(T2DM)和相关合并症的临床介绍和结果的数据缺乏数据。该研究的目的:我们描述并比较了症状Covid19阳性T2DM糖尿病患者(n = 59)的临床介绍和放射性和血液学数据与另一种非糖尿病症状Covid19阳性患者(n = 244)诊断出来同时从1月20日至5月到2020年5月。相关的合并性是分类的,并且计算了Charlson合并症指数。评估了包括住院时间,重症监护单元(ICU)持续时间(ICU)的持续时间,机械通气持续时间和O2 -Spplingation持续时间的结果。结果:症状性Covid19阳性患者T2DM的患病率为59/303(= 19.5%)。糖尿病患者的高血压患病率较高,慢性肾脏疾病(CKD)和心脏功能障碍[冠心病(CHD)]​​和充血性心力衰竭(CHF)。 T2DM患者(2.4±1.6)与非糖尿病患者(0.28±0.8; p:<0.001),Charlson合并症得分显着高。临床和放射学上,T2DM患者患有肺炎的百分比显着,严重的肺炎和ARDS与非糖尿病患者。与非糖尿病患者相比,血液活性蛋白(CRP),糖尿病患者具有明显较高的C反应蛋白(CRP),绝对中性粒细胞计数(ANC)和较低的淋巴细胞和嗜酸性粒细胞计数。它们具有显着提高的收缩性和舒张性血压,较长的住院时间,ICU停留,机械通风和氧气疗法。 CRP在ICU中停留的持续时间和氧气补充的持续时间(r = 0.37和0.42; p:<0.01),CRP显着相关。结论:T2DM患者对Covid 19的炎症反应较高,具有较高的绝对中性嗜含量计数(ANC)和具有较低淋巴细胞和嗜酸性嗜嗜酸性嗜嗜酸性核心的CRP。糖尿病患者具有更多的合并性和更具侵蚀性的疾病,具有更高的ICU入场率和更长的住院和氧气使用。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号